2,126 results match your criteria International Journal of Chronic Obstructive Pulmonary Disease [Journal]


Risks of budesonide/formoterol for the treatment of stable COPD: a meta-analysis.

Int J Chron Obstruct Pulmon Dis 2019 1;14:757-766. Epub 2019 Apr 1.

Department of Anesthesiology, The Second Affiliated Hospital of Nanchang University, No. 1 Minde Road, Nanchang, 330006, Jiangxi, China,

Purpose: The aim of this study was to investigate the comparative risks of budesonide/formoterol, versus placebo or monotherapies, for the treatment of patients with stable COPD.

Materials And Methods: We undertook a systematic search of the literature in PubMed, Embase, and the Cochrane Central Register of Controlled Trials, for randomized controlled trials (RCTs) comparing budesonide/formoterol with control regimens for the treatment of patients with stable COPD and at least 12 weeks of follow-up, meeting the inclusion criteria. Studies were reviewed, and OR with corresponding 95% CI was used to pool the results. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/COPD.S192166DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6448539PMC

The six-minute stepper test is related to muscle strength but cannot substitute for the one repetition maximum to prescribe strength training in patients with COPD.

Int J Chron Obstruct Pulmon Dis 2019 29;14:767-774. Epub 2019 Mar 29.

Normandie University, UNIROUEN, UPRES EA 3830, Rouen University Hospital, Haute Normandie Research and Biomedical Innovation, Rouen, France,

Purpose: There are many barriers to pulmonary rehabilitation, including a limited access to evaluation centers. To cope with these difficulties, field tests are often used to prescribe endurance training. As field tests are related to muscle strength, they could also be used to prescribe strength training and increase the access to pulmonary rehabilitation in rural area. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/COPD.S193585DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6445245PMC
March 2019
1 Read

Trends and hospital outcomes of lung transplantation among patients with and without chronic obstructive pulmonary disease in Spain: a national population-based study (2001-2015).

Int J Chron Obstruct Pulmon Dis 2019 27;14:729-737. Epub 2019 Mar 27.

Preventive Medicine and Public Health Teaching and Research Unit, Health Sciences Faculty, Rey Juan Carlos University, Alcorcón, Madrid, Spain,

Purpose: To describe trends from 2001 to 2015 in incidence and in-hospital outcomes of patients suffering or not suffering from COPD who had undergone lung transplantation (LTx) in Spain.

Methods: We used the Spanish National Hospital Discharge Database to select all admissions for LTx. Incidence was estimated overall and according to the presence of COPD. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/COPD.S189010DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6443219PMC
March 2019
1 Read

A clinical prediction model for hospitalized COPD exacerbations based on "treatable traits".

Int J Chron Obstruct Pulmon Dis 2019 27;14:719-728. Epub 2019 Mar 27.

Department of Respiratory and Critical Care Medicine, Changi General Hospital, Singapore,

Background: Assessing risk of future exacerbations is an important component in COPD management. History of exacerbation is a strong and independent predictor of future exacerbations, and the criterion of ≥2 nonhospitalized or ≥1 hospitalized exacerbation is often used to identify high-risk patients in whom therapy should be intensified. However, other factors or "treatable traits" also contribute to risk of exacerbation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/COPD.S194922DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6443227PMC
March 2019
1 Read

Determinants of airflow limitation in Danish adults - findings from the Health2006 cohort.

Int J Chron Obstruct Pulmon Dis 2019 26;14:713-718. Epub 2019 Mar 26.

Department of Respiratory Medicine, Hvidovre Hospital, Hvidovre, Denmark,

Background And Aim: Airflow limitation may be found in patients with both asthma and COPD and is often associated with more symptoms and poorer outcome. We aimed to identify factors associated with airflow limitation in a well-characterized, population-based sample of adults.

Methods: From the Health2006 cohort, we selected participants aged ≥35 years at enrolment (n=2,959). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/COPD.S173815DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6440446PMC
March 2019
1 Read

LncRNAs NR-026690 and ENST00000447867 are upregulated in CD4 T cells in patients with acute exacerbation of COPD.

Int J Chron Obstruct Pulmon Dis 2019 26;14:699-711. Epub 2019 Mar 26.

Department of Respiratory and Critical Care Medicine, Key Laboratory of Pulmonary Diseases of Health Ministry, Key Cite of National Clinical Research Center for Respiratory Disease, Tongji Hospital, Tongji Medical College, Huazhong University of Sciences & Technology, Wuhan, China,

Objective: The aim of the study was to determine the expression profile of long noncoding RNAs (lncRNAs) in CD4 T cells from COPD patients and explore the clinical value of the lncRNAs.

Methods: First, microarray analysis was performed. Differentially expressed lncRNAs were validated by quantitative real-time reverse transcription-PCR (qRT-PCR) in samples from 56 patients with acute exacerbations of COPD (AECOPD), 56 patients with stable COPD, and 35 healthy controls. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/COPD.S191815DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6440447PMC
March 2019
1 Read

A comparison of methodologies for the real-time identification of hospitalized patients with acute exacerbations of COPD.

Int J Chron Obstruct Pulmon Dis 2019 22;14:693-698. Epub 2019 Mar 22.

Center for Outcomes Research and Evaluation, Atrium Health, Charlotte, NC 28203, USA,

Background: COPD is a lung disease characterized by chronic, irreversible airway obstruction that can precipitate into acute exacerbations of COPD (AECOPD) often requiring hospitalization. Improving these outcomes will require proactive innovations in care delivery to at-risk populations. Data-driven models to identify patients with AECOPD on admission to the hospital are needed, but do not exist. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/COPD.S175296DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6435119PMC

Exacerbations and health care resource use among patients with COPD in relation to blood eosinophil counts.

Int J Chron Obstruct Pulmon Dis 2019 22;14:683-692. Epub 2019 Mar 22.

Center for Comprehensive Care in Chronic Obstructive Pulmonary Disease, Respiratory Institute, Cleveland Clinic, Cleveland, OH, USA.

Purpose: Current understanding of the relationship between COPD phenotype and health care resource utilization (HCRU) is limited. This real-world study evaluated disease burden and HCRU for COPD subgroups prone to exacerbation as defined by blood eosinophil (EOS) count and multiple inhaler triple therapy (MITT) use.

Methods: This was a large-scale, retrospective, longitudinal, observational cohort study using data from the US IBM Watson Explorys real-world database (GSK Study HO-17-18395). Read More

View Article

Download full-text PDF

Source
https://www.dovepress.com/exacerbations-and-health-care-reso
Publisher Site
http://dx.doi.org/10.2147/COPD.S194367DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6435122PMC
March 2019
2 Reads

AMPLIFY: a randomized, Phase III study evaluating the efficacy and safety of aclidinium/formoterol vs monocomponents and tiotropium in patients with moderate-to-very severe symptomatic COPD.

Int J Chron Obstruct Pulmon Dis 2019 22;14:667-682. Epub 2019 Mar 22.

AstraZeneca, Barcelona, Spain.

Background: AMPLIFY assessed the efficacy and safety of aclidinium bromide/formoterol fumarate (AB/FF) vs its monocomponents and tiotropium (TIO) in patients with moderate-to-very severe symptomatic COPD (NCT02796677).

Methods: In this 24-week, Phase III, double-dummy, active-controlled study, symptomatic patients (COPD Assessment Test score ≥10) were randomized to twice-daily AB/FF 400/12 µg, AB 400 µg, or FF 12 µg, or once-daily TIO 18 µg. Co-primary endpoints were change from baseline at week 24 in 1-hour morning post-dose FEV (AB/FF vs AB) and in pre-dose (trough) FEV (AB/FF vs FF). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/COPD.S189138DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6435124PMC

Blood pressure response to exposure to moderate altitude in patients with COPD.

Int J Chron Obstruct Pulmon Dis 2019 14;14:659-666. Epub 2019 Mar 14.

Department of Pulmonology and Sleep Disorders Centre, University Hospital of Zurich, Zurich, Switzerland,

Purpose: Patients with COPD might be particularly susceptible to hypoxia-induced autonomic dysregulation. Decreased baroreflex sensitivity (BRS) and increased blood pressure (BP) variability (BPV) are markers of impaired cardiovascular autonomic regulation and there is evidence for an association between decreased BRS/increased BPV and high cardiovascular risk. The aim of this study was to evaluate the effect of short-term exposure to moderate altitude on BP and measures of cardiovascular autonomic regulation in COPD patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/COPD.S194426DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6421900PMC
March 2019
6 Reads

Cost-effectiveness of the COPD Patient Management European Trial home-based disease management program.

Int J Chron Obstruct Pulmon Dis 2019 14;14:645-657. Epub 2019 Mar 14.

Department of Pneumology, Fédération de Médecine Translationnelle de Strasbourg (FMTS), Université de Strasbourg, Strasbourg, France.

Purpose: Efficient management of COPD represents an international challenge. Effective management strategies within the means of limited health care budgets are urgently required. This analysis aimed to evaluate the cost-effectiveness of a home-based disease management (DM) intervention vs usual management (UM) in patients from the COPD Patient Management European Trial (COMET). Read More

View Article

Download full-text PDF

Source
https://www.dovepress.com/cost-effectiveness-of-the-copd-pat
Publisher Site
http://dx.doi.org/10.2147/COPD.S173057DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6421871PMC
March 2019
4 Reads

Improving uptake and completion of pulmonary rehabilitation in COPD with lay health workers: feasibility of a clinical trial.

Int J Chron Obstruct Pulmon Dis 2019;14:631-643. Epub 2019 Mar 12.

Department of Clinical, Educational and Health Psychology, University College London, London, UK.

Purpose: This study was designed to evaluate the feasibility of a cluster randomized controlled trial to test the efficacy of lay health workers (LHWs) in improving the uptake and completion of pulmonary rehabilitation (PR) in the treatment of COPD.

Materials And Methods: LHWs, trained in confidentiality, role boundaries, and behavior change techniques, supported patients newly referred for PR. Interactions between LHWs and participants were recorded with smartphones. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/COPD.S188731DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6419591PMC
March 2019
2 Reads

Randomized dose-finding study of batefenterol via dry powder inhaler in patients with COPD.

Int J Chron Obstruct Pulmon Dis 2019;14:615-629. Epub 2019 Mar 8.

GSK, Research and Development, Collegeville, PA, USA.

Background: Batefenterol is a novel bifunctional muscarinic antagonist β-agonist in development for COPD. The primary objective of this randomized, double-blind, placebo-controlled, active comparator, Phase IIb study was to model the dose-response of batefenterol and select a dose for Phase III development.

Patients And Methods: Patients aged ≥40 years with COPD and FEV ≥30% and ≤70% predicted normal were randomized equally to batefenterol 37. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/COPD.S190603DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6413745PMC

COPD classification models and mortality prediction capacity.

Int J Chron Obstruct Pulmon Dis 2019;14:605-613. Epub 2019 Mar 7.

Respiratory Department, Hospital Galdakao-Usansolo, Galdakao, Bizkaia, Spain,

Objective: Our aim was to assess the impact of comorbidities on existing COPD prognosis scores.

Patients And Methods: A total of 543 patients with COPD (FEV <80% and FEV/FVC <70%) were included between January 2003 and January 2004. Patients were stable for at least 6 weeks before inclusion and were followed for 5 years without any intervention by the research team. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/COPD.S184695DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6410748PMC
March 2019
1 Read

Eosinophil levels predict lung function deterioration in apparently healthy individuals.

Int J Chron Obstruct Pulmon Dis 2019;14:597-603. Epub 2019 Mar 7.

Division of Pulmonary Medicine, Barzilai Medical Center, Faculty of Health Sciences, Ben-Gurion University, Ashkelon, Israel,

Background: While chronic respiratory diseases are among the leading causes of mortality and morbidity worldwide, little is known about the effect of blood eosinophil levels on lung function trajectories among healthy individuals.

Methods: We analyzed data of apparently healthy individuals (n=18,089) recruited for the Tel Aviv Medical Center Inflammation Survey. Blood eosinophil levels were compared between participants with normal and those with abnormal lung function. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/COPD.S192594DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6410751PMC

Prevalence and factors associated with suboptimal peak inspiratory flow rates in COPD.

Int J Chron Obstruct Pulmon Dis 2019;14:585-595. Epub 2019 Mar 1.

Division of Pulmonary Diseases and Critical Medicine, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA,

Purpose: Adequate peak inspiratory flow rate (PIFR) is required for drug dispersion with dry powder inhalers (DPIs). Prevalence of PIFR discordance (suboptimal PIFR with prescribed inhalers) and factors influencing device-specific PIFR are unclear in COPD. The objective of this study was to determine the prevalence of PIFR discordance and associated clinical factors in a stable COPD population. Read More

View Article

Download full-text PDF

Source
https://www.dovepress.com/prevalence-and-factors-associated-
Publisher Site
http://dx.doi.org/10.2147/COPD.S195438DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6402615PMC
March 2019
6 Reads
2.732 Impact Factor

Differences in plasma amino acid levels in patients with and without bacterial infection during the early stage of acute exacerbation of COPD.

Int J Chron Obstruct Pulmon Dis 2019;14:575-583. Epub 2019 Mar 1.

Pulmonary Division, Department of Internal Medicine, Sanyudo Hospital, Yonezawa, Japan,

Purpose: No consensus has been reached regarding appropriate nutritional intervention and rehabilitation during early acute exacerbation of COPD (AECOPD). Given the individual differences in symptoms of AECOPD, patients should be classified by their pathology. For example, it is known that there are differences in the inflammatory response between AECOPD with and without bacterial infection. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/COPD.S188422DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6402618PMC

Clinical phenotypes of COPD and health-related quality of life: a cross-sectional study.

Int J Chron Obstruct Pulmon Dis 2019;14:565-573. Epub 2019 Mar 1.

Department of Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia,

Introduction: The Spanish COPD guideline (GesEPOC) classifies COPD into four clinical phenotypes based on the exacerbation frequency and dominant clinical manifestations. In this study, we compared the disease-specific health-related quality of life (HRQoL) of patients with different clinical phenotypes.

Methods: This was a cross-sectional study of patients with COPD attending the respiratory medicine clinic of University of Malaya Medical Centre from 1 June 2017 to 31 May 2018. Read More

View Article

Download full-text PDF

Source
https://www.dovepress.com/clinical-phenotypes-of-copd-and-he
Publisher Site
http://dx.doi.org/10.2147/COPD.S196109DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6402617PMC
March 2019
5 Reads

Ultrafine particles in airways: a novel marker of COPD exacerbation risk and inflammatory status.

Int J Chron Obstruct Pulmon Dis 2019;14:557-564. Epub 2019 Mar 1.

Division of Allergy and Clinical Immunology, Bnai Zion Medical Center, Rappaport Faculty of Medicine, Technion - Institute of Technology, Haifa, Israel.

Purpose: Ultrafine particles (UFP) are toxic due to their small size and penetration into deeper lung compartments. We aimed to evaluate the exhaled breath condensate (EBC)-UFP content as a reflection of inflammation and oxidative stress status in COPD patients and as an exacerbation risk marker.

Methods: EBC was collected by conventional methods. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/COPD.S187560DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6402613PMC
March 2019
1 Read

COPD patients' characteristics, usual care, and adherence to guidelines: the Greek UNLOCK study.

Int J Chron Obstruct Pulmon Dis 2019;14:547-556. Epub 2019 Mar 1.

Primary Care Practice, Garipa, Herkalion, Crete, Greece.

Purpose: GOLD guidelines classify COPD patients into A-D groups based on health status as assessed by COPD Assessment Test (CAT) or mMRC tools and exacerbations and recommend single or dual long-acting bronchodilators as maintenance therapy, with additional inhaled corticosteroids (ICS) if the disease remains uncontrolled. We aimed to classify primary care COPD patients into A-D groups, assess usual treatment and adherence to guidelines, potential mismatches between CAT-and mMRC-based classification and described symptoms within groups.

Patients And Methods: A total of 257 primary care COPD patients were enrolled between 2015 and 2016 in Greece. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/COPD.S185362DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6402614PMC
March 2019
1 Read

Extrafine triple therapy delays COPD clinically important deterioration vs ICS/LABA, LAMA, or LABA/LAMA.

Int J Chron Obstruct Pulmon Dis 2019;14:531-546. Epub 2019 Feb 28.

Section of Cardiorespiratory and Internal Medicine, Department of Medical Sciences, University of Ferrara, Ferrara, Italy.

Background: Current pharmacological therapies for COPD improve quality of life and symptoms and reduce exacerbations. Given the progressive nature of COPD, it is arguably more important to understand whether the available therapies are able to delay clinical deterioration; the concept of "clinically important deterioration" (CID) has therefore been developed. We evaluated the efficacy of the single-inhaler triple combination beclometasone dipropionate, formoterol fumarate, and glycopyrronium (BDP/FF/G), using data from three large 1-year studies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/COPD.S196383DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6400232PMC
February 2019
1 Read

Survival in the Swedish cohort with alpha-1-antitrypsin deficiency, up to the age of 43-45 years.

Int J Chron Obstruct Pulmon Dis 2019;14:525-530. Epub 2019 Feb 28.

Department of Respiratory Medicine and Allergology, Skåne University Hospital, Lund University, Malmö, Sweden,

Background: Alpha-1-antitrypsin deficiency (AATD) is a hereditary disorder. AATD is a known risk factor for the development of emphysema and liver disease. A cohort of severe (PiZZ) and moderate (PiSZ) AAT-deficient newborn infants was identified by the Swedish national neonatal AAT screening in 1972-1974 and has been followed up since birth. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/COPD.S183205DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6400233PMC
February 2019
2 Reads

Improving usability and maintaining performance: human-factor and aerosol-performance studies evaluating the new reusable Respimat inhaler.

Int J Chron Obstruct Pulmon Dis 2019;14:509-523. Epub 2019 Mar 5.

Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am Rhein 55216, Germany,

Purpose: The Respimat is a handheld, propellant-free, soft-mist inhaler. Observations by patients and physicians prompted development of an improved second-generation Respimat inhaler. Human-factor studies assessing the usability of the new inhaler and in vitro assessment of aerosol performance are important to demonstrate functionality of the updated inhaler. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/COPD.S190639DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6407979PMC
March 2019
1 Read
2.732 Impact Factor

Disrupted resting-state spontaneous neural activity in stable COPD.

Int J Chron Obstruct Pulmon Dis 2019;14:499-508. Epub 2019 Feb 27.

Department of Radiology, The First Affiliated Hospital, Nanchang University, Nanchang, People's Republic of China,

Introduction And Aim: Abnormal brain structure and function in COPD has been reported on MRI. However, the deficit in local synchronization of spontaneous activity in patients with stable COPD remains unknown. The main aim of the present study was to explore spontaneous brain activity in patients with COPD compared with normal controls using the regional homogeneity (ReHo) method based on resting-state functional MRI. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/COPD.S190671DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6398400PMC
February 2019
2 Reads

Longitudinal comparison of outcomes in patients with smoking-related asthma-COPD overlap and in non-smoking asthmatics with incomplete reversibility of airway obstruction.

Int J Chron Obstruct Pulmon Dis 2019;14:493-498. Epub 2019 Feb 27.

Research Center, Quebec Heart and Lung Institute-Laval University, Quebec, QC, Canada,

Background: There is a need to characterize the impact of the smoking status on the clinical course of asthmatics with incomplete reversibility of airway obstruction (IRAO).

Objective: To compare longitudinal health care use, symptom control, and medication needs between smoking and non-smoking asthmatics with IRAO.

Materials And Methods: This was a 12-month follow-up of a cross-sectional study comparing asthmatics with IRAO according to their tobacco exposure. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/COPD.S192003DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6398407PMC
February 2019
4 Reads

Efficacy of aclidinium/formoterol 400/12 µg, analyzed by airflow obstruction severity, age, sex, and exacerbation history: pooled analysis of ACLIFORM and AUGMENT.

Int J Chron Obstruct Pulmon Dis 2019;14:479-491. Epub 2019 Feb 26.

AstraZeneca, Barcelona, Spain.

Background: Aclidinium/formoterol 400/12 µg is a twice-daily maintenance bronchodilator for COPD. This post hoc study evaluated aclidinium/formoterol vs aclidinium 400 µg, formoterol 12 µg, or placebo in patient subgroups.

Patients And Methods: Data were pooled from two 24-week Phase III clinical trials (ACLIFORM and AUGMENT). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/COPD.S185502DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6396834PMC
February 2019

Exacerbations of Chronic Obstructive Pulmonary Disease Tool to assess the efficacy of acute treatment.

Int J Chron Obstruct Pulmon Dis 2019;14:471-478. Epub 2019 Feb 25.

Department of Internal Medicine, Division of Pulmonary and Critical Care Medicine, Chungnam National University College of Medicine, Daejeon, Republic of Korea,

Background And Objective: The Exacerbations of Chronic Obstructive Pulmonary Disease Tool-Patient-Reported Outcomes (EXACT-PRO) has been suggested as a reliable and valid measure for early assessment of COPD exacerbations and perceived recovery. However, there has been no evidence for EXACT-PRO efficacy in assessing recovery from treatment in a randomized controlled trial. The study evaluated the reliability, validity, and responsiveness of EXACT-PRO for the evaluation of the efficacy of acute treatment in patients with COPD exacerbation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/COPD.S189300DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6394236PMC
February 2019
4 Reads

Efficacy and safety of glycopyrrolate in patients with COPD by reversibility: pooled analysis of GEM1 and GEM2 12-week studies.

Int J Chron Obstruct Pulmon Dis 2019;14:461-470. Epub 2019 Feb 19.

Sunovion Pharmaceuticals Inc, Marlborough, MA, USA.

Purpose: Bronchodilator reversibility has been reported in patients with COPD, although correlations between reversibility and treatment response are unclear. The effect of reversibility on lung function, health status, and dyspnea was assessed in patients with moderate-to-severe COPD receiving glycopyrrolate (GLY) 15.6 µg twice daily vs placebo in the Glycopyrrolate Effect on syMptoms and lung function 1 and 2 (GEM1 and GEM2) replicate, 12-week, placebo-controlled studies. Read More

View Article

Download full-text PDF

Source
https://www.dovepress.com/efficacy-and-safety-of-glycopyrrol
Publisher Site
http://dx.doi.org/10.2147/COPD.S194102DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6388797PMC
February 2019
5 Reads
2.732 Impact Factor

Costen's syndrome and COPD.

Authors:
Bruno Bordoni

Int J Chron Obstruct Pulmon Dis 2019 18;14:457-460. Epub 2019 Feb 18.

Foundation Don Carlo Gnocchi IRCCS, Department of Cardiology, Institute of Hospitalization and Care with Scientific Address, Milan 20100, Italy,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/COPD.S200787DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6388777PMC
March 2019
2 Reads
2.732 Impact Factor

Long-term cost-effectiveness of the fixed-dose combination of tiotropium plus olodaterol based on the DYNAGITO trial results.

Int J Chron Obstruct Pulmon Dis 2019;14:447-456. Epub 2019 Feb 18.

institute for Medical Technology Assessment (iMTA), Erasmus University Rotterdam, Rotterdam, the Netherlands,

Purpose: Combinations of long-acting bronchodilators are recommended to reduce the rate of COPD exacerbations. Evidence from the DYNAGITO trial showed that the fixed-dose combination of tiotropium + olodaterol reduced the annual rate of total exacerbations (<0.05) compared with tiotropium monotherapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/COPD.S191031DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6388779PMC
February 2019
2 Reads

Spirometry evaluation to assess performance of a claims-based predictive model identifying patients with undiagnosed COPD.

Int J Chron Obstruct Pulmon Dis 2019;14:439-446. Epub 2019 Feb 15.

Boehringer Ingelheim, Ridgefield, CT, USA.

Background: A claims-based model to predict patients likely to have undiagnosed COPD was developed by Moretz et al in 2015. This study aims to assess the performance of the aforementioned model using prospectively collected spirometry data.

Methods: A study population aged 40-89 years enrolled in a Medicare Advantage plan with prescription drug coverage or commercial health plan and without a claim for COPD diagnosis was identified from April 1, 2012 to March 31, 2016 in the Humana claims database. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/COPD.S187947DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6388795PMC
February 2019
7 Reads

No impact of exacerbation frequency and severity on the physical activity decline in COPD: a long-term observation.

Int J Chron Obstruct Pulmon Dis 2019;14:431-437. Epub 2019 Feb 15.

Pulmonary Division, University Hospital of Zurich, Zurich, Switzerland,

Introduction: COPD exacerbations are associated with a concomitant profound reduction in daily physical activity (PA). Thereby, exacerbation frequency and severity may have an amplifying effect. Whether the reduced level of PA returns to the level prior to exacerbation or has a sustained negative impact on activity behavior over time is unclear. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/COPD.S188710DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6388775PMC
February 2019

24-hour accelerometry in COPD: Exploring physical activity, sedentary behavior, sleep and clinical characteristics.

Int J Chron Obstruct Pulmon Dis 2019;14:419-430. Epub 2019 Feb 18.

School of Sport, Exercise and Health Sciences, Loughborough University, Loughborough, UK,

Background: The constructs and interdependency of physical behaviors are not well described and the complexity of physical activity (PA) data analysis remains unexplored in COPD. This study examined the interrelationships of 24-hour physical behaviors and investigated their associations with participant characteristics for individuals with mild-moderate airflow obstruction and healthy control subjects.

Patients And Methods: Vigorous PA (VPA), moderate-to-vigorous PA (MVPA), light PA (LPA), stationary time (ST), average movement intensity (vector magnitude counts per minute), and sleep duration for 109 individuals with COPD and 135 healthy controls were obtained by wrist-worn accelerometry. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/COPD.S183029DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6388788PMC
February 2019
4 Reads

Area under the forced expiratory flow-volume loop in spirometry indicates severe hyperinflation in COPD patients.

Int J Chron Obstruct Pulmon Dis 2019;14:409-418. Epub 2019 Feb 14.

Laboratory of Respiratory Diseases, Department of Chronic Diseases, Metabolism and Ageing, Katholieke Universiteit Leuven, Leuven, Belgium,

Background: Severe hyperinflation causes detrimental effects such as dyspnea and reduced exercise capacity and is an independent predictor of mortality in COPD patients. Static lung volumes are required to diagnose severe hyperinflation, which are not always accessible in primary care. Several studies have shown that the area under the forced expiratory flow-volume loop (AreaFE) is highly sensitive to bronchodilator response and is correlated with residual volume/total lung capacity (RV/TLC), a common index of air trapping. Read More

View Article

Download full-text PDF

Source
https://www.dovepress.com/area-under-the-forced-expiratory-f
Publisher Site
http://dx.doi.org/10.2147/COPD.S185931DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6388784PMC
February 2019
6 Reads

COPD and the risk of mild cognitive impairment and dementia: a cohort study based on the Chinese Longitudinal Health Longevity Survey.

Authors:
Fei Xie Lixin Xie

Int J Chron Obstruct Pulmon Dis 2019;14:403-408. Epub 2019 Feb 13.

Department of Pulmonary and Critical Care Medicine, Chinese PLA General Hospital, Beijing 100853, China,

Background: COPD may lead to cognitive impairment or even dementia. However, the current conclusions are inconsistent with little evidence from prospective, large-sample studies. This study was designed to explore the association of COPD with mild cognitive impairment (MCI) and dementia risk based on a cohort study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/COPD.S194277DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6388769PMC
February 2019
1 Read

When to use single-inhaler triple therapy in COPD: a practical approach for primary care health care professionals.

Int J Chron Obstruct Pulmon Dis 2019;14:391-401. Epub 2019 Feb 13.

Medicines Evaluation Unit, University of Manchester, Manchester University NHS Foundation Hospital Trust, Manchester, UK,

While single-inhaler triple therapy (SITT) devices were not available when the Global Initiative for Chronic Obstructive Lung Disease strategy and National Institute for Health and Care Excellence guidelines were developed, two devices are now available in the UK. This paper offers practical, patient-focused advice to optimize placement of SITT in the management of COPD. A survey of UK health care professionals (HCPs) identified issues around, and attitudes toward, SITT, which informed a multidisciplinary expert panel's discussions. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/COPD.S173901DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6388781PMC
February 2019
2 Reads

A prospective study of the clinical outcomes and prognosis associated with comorbid COPD in the atrial fibrillation population.

Int J Chron Obstruct Pulmon Dis 2019;14:371-380. Epub 2019 Feb 12.

Servicio de Cardiología, Hospital Universitario Santiago de Compostela, Santiago de Compostela, Spain,

Background: Patients with COPD are at higher risk of presenting with atrial fibrillation (AF). Information about clinical outcomes and optimal medical treatment of AF in the setting of COPD remains missing. We aimed to describe the prevalence of COPD in a sizeable cohort of real-world AF patients belonging to the same healthcare area and to examine the relationship between comorbid COPD and AF prognosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/COPD.S174443DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6388772PMC
February 2019
1 Read

Medication adherence and persistence in chronic obstructive pulmonary disease patients receiving triple therapy in a USA commercially insured population.

Int J Chron Obstruct Pulmon Dis 2019;14:343-352. Epub 2019 Feb 19.

Analysis Group Inc., Boston, MA, USA.

Introduction: This longitudinal, retrospective cohort study of patients with COPD describes baseline characteristics, adherence, and persistence following initiation of inhaled corticosteroids (ICS)/long-acting β-agonists (LABA)/long-acting muscarinic antagonists (LAMA) from multiple inhaler triple therapy (MITT).

Methods: Patients aged ≥40 years receiving MITT between January 2012 and September 2015 were identified from the IQVIA™ Real-world Data Adjudicated Claims-USA database. MITT was defined as subjects with ≥1 overlapping days' supply of three COPD medications (ICS, LABA, and LAMA). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/COPD.S184653DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6388782PMC
February 2019
1 Read

Quantitative CT assessment of bronchial and vascular alterations in severe precapillary pulmonary hypertension.

Int J Chron Obstruct Pulmon Dis 2019;14:381-389. Epub 2019 Feb 11.

Université de Bordeaux, Centre de Recherche Cardio-Thoracique de Bordeaux, U1045, F-33000 Bordeaux, France,

Background: Little is known about in vivo alterations at bronchial and vascular levels in severe pulmonary hypertension (PH) of different etiologies. We aimed to compare quantitative computed tomography (CT) data from the following three groups of severe precapillary PH patients: COPD, idiopathic pulmonary arterial hypertension (iPAH), and chronic thromboembolic PH (CTEPH).

Patients And Methods: This study was approved by the institutional review board. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/COPD.S177638DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6377046PMC
February 2019
1 Read

Longitudinal change of FEV and inspiratory capacity: clinical implication and relevance to exacerbation risk in patients with COPD.

Int J Chron Obstruct Pulmon Dis 2019;14:361-369. Epub 2019 Feb 4.

Department of Internal Medicine, Division of Pulmonary and Allergy Medicine, Konkuk University School of Medicine, Seoul, Republic of Korea,

Background And Objective: FEV is the gold standard for assessment of COPD. We compared efficacy of FEV, inspiratory capacity (IC), and IC to total lung capacity (TLC) ratio in the evaluation of COPD and their association with exacerbation.

Methods: We analyzed the association of dyspnea severity, quality of life status, and lung function with lung function measurements and exacerbation risk in 982 patients enrolled in the Korea COPD Subgroup Registry and Subtype Research study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/COPD.S189384DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6366360PMC
February 2019

Early management of COPD: where are we now and where do we go from here? A Delphi consensus project.

Int J Chron Obstruct Pulmon Dis 2019;14:353-360. Epub 2019 Feb 4.

Istituti Clinici Scientifici Maugeri, IRCCS di Cassano delle Murge, Cassano delle Murge (BA), Italy.

Purpose: There is a lack of consensus on the most appropriate early diagnostic strategy, criteria for early access to treatment and follow-up approach for patients with COPD.

Materials And Methods: A Delphi consensus project investigated the early management of COPD. We formulated two questionnaires for completion by pneumologists in Italy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/COPD.S176662DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6366359PMC
February 2019

Greater eosinophil counts at first COPD hospitalization are associated with more readmissions and fewer deaths.

Int J Chron Obstruct Pulmon Dis 2019;14:331-341. Epub 2019 Jan 30.

Research Center, Centre Hospitalier Universitaire de Sherbrooke (CHUS), Sherbrooke, QC, Canada,

Purpose: The impacts of high blood eosinophil count (HBEC) at admission for COPD exacerbation on posthospitalization outcomes are still unclear. Previous studies have focused on its associations with first readmission rates; yet, its impacts on longitudinal outcomes such as subsequent readmissions still have to be explored. The main objective of this study is to investigate outcomes associated with HBEC following a first hospitalization for COPD exacerbation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/COPD.S187375DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6363487PMC
January 2019

Evaluation of plasma antimicrobial peptide LL-37 and nuclear factor-kappaB levels in stable chronic obstructive pulmonary disease.

Int J Chron Obstruct Pulmon Dis 2019;14:321-330. Epub 2019 Jan 25.

Department of Biochemistry, Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa, Istanbul, Turkey,

Background: Antimicrobial peptides are effectors of host defence against infection and inflammation and can encourage wound repair.

Objectives: The objectives of this study were to investigate the plasma antimicrobial peptide LL-37 and nuclear factor-kappaB (NF-κB) levels in patients with stable COPD compared with a control group and to highlight their importance in immune inflammation.

Methods: One hundred and thirty-eight stable COPD patients and 33 control subjects were enrolled in the study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/COPD.S185602DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6354692PMC
January 2019

Phenotyping and outcomes of hospitalized COPD patients using rapid molecular diagnostics on sputum samples.

Int J Chron Obstruct Pulmon Dis 2019;14:311-319. Epub 2019 Jan 23.

Centre for Heart Lung Innovation, James Hogg Research Centre, St Paul's Hospital, Vancouver, BC, Canada,

Background: Etiologies of acute exacerbations of chronic obstructive pulmonary disease (AECOPD) are heterogeneous. We phenotyped severe AECOPD based on molecular pathogen detection of sputum samples collected at hospitalization of COPD patients and determined their outcomes.

Methods: We phenotyped 72 sputum samples of COPD patients who were hospitalized with a primary diagnosis of AECOPD using a molecular array that detected common bacterial and viral respiratory pathogens. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/COPD.S188186DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6350828PMC
January 2019

Short-term effects of ambient air pollution on chronic obstructive pulmonary disease admissions in Beijing, China (2013-2017).

Int J Chron Obstruct Pulmon Dis 2019;14:297-309. Epub 2019 Jan 23.

Department of Respiratory and Critical Care Medicine, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China,

Purpose: Evidence between air pollution and COPD admissions is inconsistent and limited in China. In this study, we aimed to explore the effects of air pollutants on COPD admissions in Beijing, China.

Patients And Methods: Daily COPD hospital admission visits derived from tertiary and secondary hospitals in Beijing were retrieved from January 2013 to February 2017. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/COPD.S188900DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6350834PMC
January 2019
1 Read

Efficacy of a home discharge care bundle after acute exacerbation of COPD.

Int J Chron Obstruct Pulmon Dis 2019;14:289-296. Epub 2019 Jan 22.

Pulmonary, Thoracic Oncology and Respiratory Intensive Care Department, Rouen University Hospital, Rouen, France,

Purpose: Acute exacerbations of COPD (AECOPD) are frequent and associated with a poor prognosis. A home discharge care bundle, the PRADO-BPCO program, has been set up by the French National Health System in order to reduce readmission rate after hospitalization for AECOPD. This program includes early consultations by the general practitioner, a nurse, and a physiotherapist after discharge. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/COPD.S178147DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6349078PMC
January 2019
1 Read

Changes in COPD inhaler prescriptions in the United Kingdom, 2000 to 2016.

Int J Chron Obstruct Pulmon Dis 2019;14:279-287. Epub 2019 Jan 22.

National Heart and Lung Institute, Imperial College London, London SW3 6LR, UK,

Background: Over the past two decades, there have been significant changes in the pharmacological management of COPD, due to an explosion of inhaler trials, and timely updation of national and international guidelines. We sought to describe temporal changes in prescribing practices in the United Kingdom, and some of the factors that may have influenced them.

Patients And Methods: COPD patients were identified from UK primary care nationally representative electronic healthcare records (Clinical Practice Research Datalink), between 2000 and 2016. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/COPD.S190086DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6349076PMC
January 2019

Minimal clinically important difference of 3-minute chair rise test and the DIRECT questionnaire after pulmonary rehabilitation in COPD patients.

Int J Chron Obstruct Pulmon Dis 2019;14:261-269. Epub 2019 Jan 22.

Faculty of Medicine, Université Grenoble-Alpes, Grenoble, France,

Background: The 3-minute chair rise test (3-minute CRT) and the Disability Related to COPD Tool (DIRECT) are two reproducible and valid short tests that can assess the benefit of pulmonary rehabilitation (PR) in terms of functional capacity and dyspnea in everyday activities.

Methods: We determined the minimal clinically important difference (MCID) of the DIRECT questionnaire and 3-minute CRT using distribution methods and anchor encroaches with a panel of eight standard tests in a cohort of 116 COPD patients who completed a PR program in real-life settings.

Results: The estimated MCID for the 3-minute CRT and DIRECT scores was five repetitions and two units, respectively, using separate and combined independent anchors. Read More

View Article

Download full-text PDF

Source
https://www.dovepress.com/minimal-clinically-important-diffe
Publisher Site
http://dx.doi.org/10.2147/COPD.S187567DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6349077PMC
January 2019
8 Reads
2.732 Impact Factor

Male current smokers have low awareness and optimistic bias about COPD: field survey results about COPD in Korea.

Int J Chron Obstruct Pulmon Dis 2019;14:271-277. Epub 2019 Jan 21.

Department of Pulmonary, Allergy and Critical Care Medicine, Hallym University Sacred Heart Hospital, Anyang-si, South Korea,

Background: Smoking is a major risk factor for COPD. However, there is low COPD awareness among smokers. We conducted a field survey to investigate COPD awareness, optimistic bias associated with COPD, and COPD prevalence (using handheld spirometry) among current male smokers. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/COPD.S189859DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6345187PMC
January 2019
2 Reads
2.732 Impact Factor

Real-life effectiveness of indacaterol-glycopyrronium after switching from tiotropium or salmeterol/fluticasone therapy in patients with symptomatic COPD: the POWER study.

Int J Chron Obstruct Pulmon Dis 2019;14:249-260. Epub 2019 Jan 18.

Department of Medicine, McMaster University, Firestone Institute for Respiratory Health, Hamilton, ON, Canada.

Purpose: In contrast to randomized controlled trials (RCTs), changes in maintenance pharmacotherapy in clinical practice occur without a washout period. The Prospective cohort study for the real-life effectiveness evaluation of glycOpyrronium With indacatERol combination in the management of COPD in Canada (POWER) study evaluated the real-life effectiveness of indacaterol/glycopyrronium (IND/GLY) following a direct switch from a long-acting muscarinic antagonist (LAMA, tiotropium) or long-acting β-agonist (LABA)/inhaled corticosteroid (ICS) maintenance treatment (salmeterol/fluticasone [SFC]).

Methods: POWER was a single-cohort, prospective, multicenter, interventional study in which patients with moderate-to-severe COPD, who remained symptomatic on their current treatment of once-daily (od) tiotropium 18 µg or twice-daily (bid) SFC (any dose), were switched to treatment with open-label IND/GLY 110/50 µg od for 16 weeks. Read More

View Article

Download full-text PDF

Source
https://www.dovepress.com/real-life-effectiveness-of-indacat
Publisher Site
http://dx.doi.org/10.2147/COPD.S185485DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6343749PMC
January 2019
9 Reads